Pfizer Inc v. Biocon Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pfizer Inc. (Delaware) and PF Prism Imb BV. (Netherlands)
  • Defendant: Biocon Limited (India), Biocon Pharma Limited (India), and Biocon Pharma, Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00441, D. Del., 04/16/2026
• Venue Allegations: Venue is alleged to be proper for the foreign defendants (Biocon Limited and Biocon Pharma Limited) as they are not residents of the United States and may be sued in any judicial district. Venue is alleged to be proper for the domestic defendant (Biocon Pharma, Inc.) as it is a Delaware corporation and therefore resides in the District of Delaware.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of CIBINQO® (abrocitinib) constitutes an act of patent infringement.
• Technical Context: The technology relates to pyrrolo[2,3-d]pyrimidine chemical compounds that function as selective Janus Kinase (JAK) inhibitors for treating inflammatory and autoimmune diseases, such as atopic dermatitis.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 221262 with a Paragraph IV Certification, challenging U.S. Patent No. 9,035,074, which is listed in the FDA's "Orange Book" as covering Plaintiff's CIBINQO® product.

Case Timeline

Date	Event
2013-02-22	'074 Patent Priority Date
2015-05-19	'074 Patent Issue Date
2026-03-11	Date of Biocon's Notice Letter to Pfizer
2026-04-16	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

• Patent Identification: U.S. Patent No. 9,035,074, "Pyrrolo[2,3-D]Pyrimidine Derivates", issued May 19, 2015.

The Invention Explained

• Problem Addressed: The patent addresses the need for new therapeutic compounds that can treat diseases associated with inappropriate protein kinase activity, particularly diseases mediated by the Janus Kinase (JAK) family of enzymes (e.g., autoimmune and inflammatory disorders) ʼ074 Patent, col. 1:19-34 The patent specifically notes the desirability of selectively inhibiting the JAK1 enzyme over the JAK2 enzyme to modulate immune activity while avoiding potential side effects associated with JAK2-dependent signaling pathways ʼ074 Patent, col. 2:1-9
• The Patented Solution: The patent discloses a class of chemical compounds, pyrrolo[2,3-d]pyrimidine derivatives, designed to function as selective JAK inhibitors, particularly for JAK1 ʼ074 Patent, abstract '074 Patent, col. 5:16-19 The core of the invention is a chemical scaffold (Formula I) with various specified substituent groups that can be modified to achieve the desired therapeutic properties ʼ074 Patent, col. 2:15-65
• Technical Importance: Developing selective JAK1 inhibitors provided a targeted therapeutic approach for immune-mediated diseases, offering a potential alternative to broader-acting immunosuppressants and aiming for an improved safety profile by minimizing off-target effects on other JAK enzymes.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" without specifying which claims will be asserted Compl. ¶35 Independent claim 1 is representative of the patent's core invention.
• Independent Claim 1 claims a compound of Formula I, or a pharmaceutically acceptable salt thereof, which is structurally defined by:
  • A pyrrolo[2,3-d]pyrimidine core structure.
  • A set of defined variable substituents (R¹, R², R³, R⁴) attached to the core.
  • A key side chain represented by the formula -X-S(O)p-Y, where X, p, and Y represent variable linkers and chemical groups.
• The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice in such litigation.

III. The Accused Instrumentality

Product Identification

• The "Biocon ANDA Product," identified as a generic version of CIBINQO® (abrocitinib) tablets in 50 mg, 100 mg, and 200 mg dosage strengths Compl. ¶16

Functionality and Market Context

• The Biocon ANDA Product is a pharmaceutical tablet whose active ingredient is abrocitinib (Compl. ¶13; Compl. ¶14). CIBINQO®, the reference listed drug, is approved for the treatment of moderate-to-severe atopic dermatitis Compl. ¶14 The complaint alleges that the Biocon ANDA Product is a "generic copy" of CIBINQO® Compl. ¶17 The filing of the ANDA itself indicates Defendants' intent to market the product as a lower-cost, therapeutically equivalent alternative to the branded drug upon receiving FDA approval Compl. ¶1 Compl. ¶16

IV. Analysis of Infringement Allegations

The complaint does not provide a claim chart or detailed infringement contentions. Instead, it alleges that Biocon's ANDA submission, which seeks FDA approval to market a generic version of abrocitinib, constitutes an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶33

Crucially, the complaint alleges that in its Notice Letter, "Biocon Pharma Limited does not contest infringement of the '074 patent" Compl. ¶35 Compl. ¶44 This suggests that the primary dispute in the case will not be over whether the abrocitinib in Defendants' product meets the limitations of the patent's claims, but rather over the validity of those claims Compl. ¶18 Because the complaint does not map claim elements to the accused product and instead indicates infringement is uncontested, a claim chart summary is not applicable.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Scope Questions: The central infringement question appears to be whether the active pharmaceutical ingredient (API) in the Biocon ANDA Product is a compound, or a pharmaceutically acceptable salt thereof, that falls within the scope of the asserted claims of the '074 patent. However, the complaint's allegation that infringement is not contested suggests this may become a stipulated issue, shifting the case's focus entirely to validity.
  • Technical Questions: Should Defendants reverse course and contest infringement, a technical question may arise concerning the specific crystalline form (polymorph), salt, or impurity profile of the abrocitinib in the Biocon ANDA product and whether it differs from the claimed composition in a legally significant way.

V. Key Claim Terms for Construction

Given the allegation that infringement is not contested, claim construction may not be a primary focus. However, should the dispute evolve, certain terms would be critical.

• The Term: "a pharmaceutically acceptable salt thereof"
• Context and Importance: This term is critical because the ANDA product may be formulated with a specific salt form of the abrocitinib API. The infringement analysis would depend on whether that specific salt qualifies as "pharmaceutically acceptable" under the established meaning of the term in the art. Practitioners may focus on this term if Biocon's product uses a novel or unconventional salt form not explicitly listed in the specification.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification provides a long, exemplary list of suitable acid and base salts, indicating that the inventors contemplated a wide variety of possible salt forms ʼ074 Patent, col. 14:52 - col. 15:20 The use of non-limiting language such as "Examples include" supports a broad interpretation covering any salt suitable for pharmaceutical use ʼ074 Patent, col. 14:54
  • Evidence for a Narrower Interpretation: The patent does not provide an explicit narrowing definition. A party arguing for a narrower scope might contend that the term should be limited by the state of the art at the time of filing, excluding salts that a person of ordinary skill would not have considered safe or effective for administration.

VI. Other Allegations

• Indirect Infringement: The complaint alleges induced infringement, stating that upon FDA approval, Defendants' marketing and the product's proposed labeling will instruct and encourage medical professionals and patients to use the generic product in an infringing manner Compl. ¶¶36-37 It also alleges contributory infringement on the basis that the Biocon ANDA Product is especially made for an infringing use and is not suitable for any substantial non-infringing use Compl. ¶38
• Willful Infringement: Willfulness is alleged based on Defendants' "full knowledge of the '074 patent" prior to the lawsuit, stemming from the patent's listing in the FDA Orange Book and the statutory ANDA notification process Compl. ¶36 Compl. ¶45 The complaint alleges Defendants proceeded without a reasonable basis for believing they would not be liable for infringement Compl. ¶36

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue for the court will be one of patent validity. The complaint asserts that Defendants do not contest infringement but have certified the '074 patent as "invalid" Compl. ¶18 Compl. ¶35 Consequently, the case will likely center on whether Defendants can prove by clear and convincing evidence that the asserted claims are invalid, for reasons such as obviousness or lack of written description.
• A second pivotal question is one of willfulness. If the patent is ultimately found valid and infringed, the court will need to determine whether Defendants' conduct-proceeding with their ANDA application despite knowledge of the '074 patent-was egregious enough to constitute willful infringement, which could expose them to enhanced damages and attorneys' fees.
• A final, though seemingly secondary, question is one of infringement defense. Will Defendants maintain their alleged "no contest" position on infringement throughout the litigation, or will they develop a non-infringement theory, potentially focusing on technical distinctions between their specific generic product and the precise scope of the patent claims?